StockData

Invivyd vs Pelthos Therapeutics

IVVD and PTHS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IVVD and PTHS compare

Invivyd is the larger company, worth 5.8 times as much as Pelthos Therapeutics ($158M against $27.4M).

Invivyd keeps more of each dollar of sales as profit, with a net margin of −184% compared with −200% at Pelthos Therapeutics.

Invivyd scores higher on the StockData Score (9 against 2 for Pelthos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIVVDPTHS
Size and price
Market cap$158M$27.4M
Share price$0.538$7.15
Change, 1 year−69.6%−79.4%
Change, 5 years−97.9%–
Beta (5Y)2.470.91
Employees12292
StockData Score
Total score9 (better)2
Valuation score3 (better)1
Growth score1 (better)0
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S2.7×0.6× (better)
P/B0.9×–
FCF yield−69.2%–
Fair value$0.983–
Margin of safety45.3%–
Growth
Revenue growth (TTM)26.3%–
Profitability
Gross margin–78.6%
Operating margin−193%−133% (better)
Net margin−184% (better)−200%
FCF margin−188%–
Return on equity−95.9%–
Return on invested capital−616%–
Financial health
Debt / equity0.00–
Interest coverage–−7.8×
Current ratio5.87 (better)1.98
Altman Z-score−4.74−1.83 (better)
Piotroski F-score55
Dividends and buybacks
Buyback yield−0.24%–
Shareholder yield−0.24%0.00% (better)
Ownership
Held by institutions79.0%35.6%
Held by insiders16.7%–
Insider net buying, 12 months−$531K$794K (better)
Short interest, % of float14.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.